Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Allissa M. Long, PharmD and Kevin W. Chamberlin, PharmD, FASCP
Advertisement
Articles by Allissa M. Long, PharmD and Kevin W. Chamberlin, PharmD, FASCP
Advertisement
Latest Updated Articles
Lefamulin (Xenleta) for Community Acquired Bacterial PneumoniaJanuary 21st 2020
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5